Circulatory Research

Phase I clinical trial on microplasmin for thromboembolic diseases

Published in Blood Weekly, June 19th, 2003

ThromboGenics Ltd., a biotechnology company focused on discovery and development of therapeutics for vascular diseases, announced the successful completion of a Phase I clinical trial of its novel therapeutic, microplasmin, a thrombolytic (clot-dissolving) agent with potential neuroprotective properties.

ThromboGenics has created, on a proprietary basis, the first stabilized and readily manufactured form of the microplasmin molecule, a recombinant DNA-derived protein, which is a truncated form of the natural human protein plasmin.

The Phase I study employed an ascending-dose, placebo-controlled, randomised, double-blind design with 59 healthy, human...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-06-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry